• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

接受抗刺突单克隆抗体治疗的2019冠状病毒病B细胞耗竭患者的预后

Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies.

作者信息

Yetmar Zachary A, Khodadadi Ryan B, Seville Maria Teresa, Brumble Lisa, O'Horo John C, Ganesh Ravindra, Razonable Raymund R

机构信息

Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.

Division of Infectious Diseases, Mayo Clinic, Scottsdale, Arizona, USA.

出版信息

Open Forum Infect Dis. 2022 Apr 14;9(7):ofac204. doi: 10.1093/ofid/ofac204. eCollection 2022 Jul.

DOI:10.1093/ofid/ofac204
PMID:35791358
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9047222/
Abstract

Antispike monoclonal antibody treatment of 180 B-cell-depleted patients with mild-to-moderate coronavirus disease 2019 (COVID-19) resulted in good outcomes overall, with only 12.2% progressing to severe disease, 9.4% requiring hospitalization, 0.6% requiring mechanical ventilation, no deaths within 30 days, and 1.8% developing persistent COVID-19. Antispike monoclonal antibodies appear effective in this immunocompromised population.

摘要

对180例轻度至中度2019冠状病毒病（COVID-19）且B细胞耗竭的患者进行抗刺突单克隆抗体治疗，总体结果良好，仅有12.2%进展为重症疾病，9.4%需要住院治疗，0.6%需要机械通气，30天内无死亡病例，1.8%发生持续性COVID-19。抗刺突单克隆抗体在这一免疫功能低下人群中似乎有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3e6/9251654/e42b0aa780b8/ofac204f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3e6/9251654/e42b0aa780b8/ofac204f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3e6/9251654/e42b0aa780b8/ofac204f1.jpg

相似文献

1
Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies.接受抗刺突单克隆抗体治疗的2019冠状病毒病B细胞耗竭患者的预后
Open Forum Infect Dis. 2022 Apr 14;9(7):ofac204. doi: 10.1093/ofid/ofac204. eCollection 2022 Jul.
2
The evaluation of risk factors for prolonged viral shedding during anti-SARS-CoV-2 monoclonal antibodies and long-term administration of antivirals in COVID-19 patients with B-cell lymphoma treated by anti-CD20 antibody.评估在接受抗 CD20 抗体治疗的 B 细胞淋巴瘤 COVID-19 患者中，使用抗 SARS-CoV-2 单克隆抗体和长期使用抗病毒药物期间，病毒持续脱落的风险因素。
BMC Infect Dis. 2024 Jul 22;24(1):715. doi: 10.1186/s12879-024-09631-3.
3
Antispike monoclonal antibodies for prevention and treatment of coronavirus disease-2019 in solid organ transplant recipients.用于预防和治疗实体器官移植受者2019冠状病毒病的抗刺突单克隆抗体。
Curr Opin Organ Transplant. 2022 Aug 1;27(4):269-276. doi: 10.1097/MOT.0000000000000981.
4
SARS-CoV-2 spike codon mutations and risk of hospitalization after antispike monoclonal antibody therapy in solid organ transplant recipients.SARS-CoV-2 刺突密码子突变与实体器官移植受者抗刺突单克隆抗体治疗后住院风险的关系。
J Med Virol. 2023 Jun;95(6):e28885. doi: 10.1002/jmv.28885.
5
Monoclonal Antibody Therapy For High-Risk Coronavirus (COVID 19) Patients With Mild To Moderate Disease Presentations (Archived)针对轻度至中度症状的高危冠状病毒（COVID-19）患者的单克隆抗体疗法（存档）
6
Treatment of persistent COVID-19 in two B-cell-depleted patients with the monoclonal antibody Sotrovimab.用单克隆抗体索托维单抗治疗两名B细胞耗竭的持续性新冠病毒病患者。
IDCases. 2022;29:e01528. doi: 10.1016/j.idcr.2022.e01528. Epub 2022 Jun 7.
7
Evaluating And Referring Patients For Outpatient Monoclonal Antibody Therapy For Coronavirus In The Emergency Department (Archived)在急诊科评估并转诊患者接受冠状病毒门诊单克隆抗体治疗（存档）
8
Association of Neutralizing Antispike Monoclonal Antibody Treatment With Coronavirus Disease 2019 Hospitalization and Assessment of the Monoclonal Antibody Screening Score.中和抗刺突单克隆抗体治疗与2019冠状病毒病住院情况的关联及单克隆抗体筛查评分评估
Mayo Clin Proc Innov Qual Outcomes. 2023 Apr;7(2):109-121. doi: 10.1016/j.mayocpiqo.2022.12.007. Epub 2023 Jan 11.
9
An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies.抗刺突严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）单克隆抗体的更新。
Indian J Pharmacol. 2022 Jan-Feb;54(1):51-57. doi: 10.4103/ijp.ijp_519_21.
10
Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.巴姆洛单抗-埃特司韦单抗和卡司瑞韦单抗-伊德维单抗治疗轻至中度 2019 冠状病毒病高危患者的严重结局发生率。
Mayo Clin Proc. 2022 May;97(5):943-950. doi: 10.1016/j.mayocp.2022.02.009. Epub 2022 Feb 23.

引用本文的文献

1
Impact of Cancer Subtype and Cancer Therapy Exposures on SARS-CoV-2 Outcomes in the Omicron and Subvariant Era.癌症亚型和癌症治疗暴露对奥密克戎及其亚型流行时代严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染结局的影响
Cancer Med. 2025 Jul;14(14):e71082. doi: 10.1002/cam4.71082.
2
A Scoping Review of Preclinical Research on Monoclonal Antibody Development for Prophylaxis and Treatment of West Nile Virus Infections.用于预防和治疗西尼罗河病毒感染的单克隆抗体开发的临床前研究范围综述
Viruses. 2025 Jun 12;17(6):845. doi: 10.3390/v17060845.
3
An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab.

本文引用的文献

1
Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies.淋巴细胞恶性肿瘤患者中 SARS-CoV-2 的持续感染。
Cancer Discov. 2022 Jan;12(1):62-73. doi: 10.1158/2159-8290.CD-21-1033. Epub 2021 Nov 9.
2
Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients.实体器官移植受者中COVID-19的单克隆抗体治疗
Open Forum Infect Dis. 2021 Jun 7;8(6):ofab255. doi: 10.1093/ofid/ofab255. eCollection 2021 Jun.
3
Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19.
一项国际多中心研究比较了奥密克戎变异株在接受奥滨尤妥珠单抗与利妥昔单抗治疗的血液系统恶性肿瘤患者中的结局。
Cancer Med. 2024 Feb;13(3):e6997. doi: 10.1002/cam4.6997.
4
Using a web platform for equitable distribution of COVID-19 monoclonal antibodies: a case study in resource allocation.利用网络平台公平分配 COVID-19 单克隆抗体：资源配置案例研究。
Front Public Health. 2023 Nov 28;11:1226935. doi: 10.3389/fpubh.2023.1226935. eCollection 2023.
5
Vaccines and therapeutics for immunocompromised patients with COVID-19.针对新冠病毒免疫功能低下患者的疫苗和治疗方法。
EClinicalMedicine. 2023 May;59:101965. doi: 10.1016/j.eclinm.2023.101965. Epub 2023 Apr 12.
6
Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates.恢复期血浆治疗曾接受 B 细胞耗竭单克隆抗体治疗的 COVID-19 患者与降低再入院率相关。
Viruses. 2023 Mar 15;15(3):756. doi: 10.3390/v15030756.
7
COVID-19 in patients with B cell immune deficiency.B 细胞免疫缺陷患者的 COVID-19 。
J Immunol Methods. 2022 Nov;510:113351. doi: 10.1016/j.jim.2022.113351. Epub 2022 Sep 7.
8
Neutralizing monoclonal antibodies against SARS-CoV-2 for COVID-19 pneumonia in a rituximab treated patient with systemic sclerosis-A case report and literature review.利妥昔单抗治疗的系统性硬化症患者中用于COVID-19肺炎的抗SARS-CoV-2中和单克隆抗体——病例报告及文献综述
Front Med (Lausanne). 2022 Aug 3;9:934169. doi: 10.3389/fmed.2022.934169. eCollection 2022.
卡西瑞维单抗-英夫西单抗治疗与轻至中度新型冠状病毒肺炎高危患者的住院率降低相关。
EClinicalMedicine. 2021 Oct;40:101102. doi: 10.1016/j.eclinm.2021.101102. Epub 2021 Aug 30.
4
Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19.静脉注射巴尼利单抗可降低 COVID-19 轻症和中症高风险患者的住院率。
J Clin Invest. 2021 Oct 1;131(19). doi: 10.1172/JCI151697.
5
Incidence, Clinical Presentation, Relapses and Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Patients Treated With Anti-CD20 Monoclonal Antibodies.抗 CD20 单克隆抗体治疗患者严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染的发生率、临床表现、复发和结局。
Clin Infect Dis. 2022 May 30;74(10):1786-1794. doi: 10.1093/cid/ciab700.
6
Severe Acute Respiratory Syndrome Coronavirus 2-Specific Monoclonal Antibody for the Treatment of Mild to Moderate Coronavirus Disease 2019 in Cancer Patients: A Single-Center Experience.用于治疗癌症患者轻至中度2019冠状病毒病的严重急性呼吸综合征冠状病毒2特异性单克隆抗体：一项单中心经验
J Infect Dis. 2022 Jan 18;225(2):352-354. doi: 10.1093/infdis/jiab406.
7
Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell-Depleted Patients.25 例 B 细胞耗竭患者接受恢复期血浆治疗新型冠状病毒肺炎的效果。
Clin Infect Dis. 2022 Apr 9;74(7):1271-1274. doi: 10.1093/cid/ciab647.
8
Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.巴姆洛单抗和卡西米单抗-伊马维单抗在轻中度 2019 冠状病毒病高危患者中的真实世界临床结局。
J Infect Dis. 2021 Oct 28;224(8):1278-1286. doi: 10.1093/infdis/jiab377.
9
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19.恢复期血浆疗法与血液系统恶性肿瘤合并 COVID-19 患者生存情况的关联
JAMA Oncol. 2021 Jun 17;7(8):1167-75. doi: 10.1001/jamaoncol.2021.1799.
10
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.疾病修正疗法与多发性硬化症中 2019 年冠状病毒病严重程度。
Ann Neurol. 2021 Apr;89(4):780-789. doi: 10.1002/ana.26028. Epub 2021 Feb 9.